Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease. Learn More

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety and versatility to defeat even the most insidious fungal diseases.

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing …

At SCYNEXIS, we believe that our innovative fungerp class of antifungals could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections …

Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of ibrexafungerp in the global market; SCYNEXIS to receive milestone payments of up to $122 million, with $10 million upfront, plus low double-digit royalty ...

SCYNEXIS regularly presents key infectious disease study data at top medical meetings. Learn More

Product. Learn more about this first-in-class, non-azole option here.

2023年7月20日 · SCYNEXIS is developing its proprietary class of enfumafungin-derived antifungal compounds (“fungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications.

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies.

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections